The Role of Losartan and Oral Magnesium Sulfate in Cisplatin Induced Nephrotoxicity in Female Rats

Hypomagnesemia is one of the nephrotoxicity signs. In addition, renin-angiotensin system may be involved in pathophysiology of kidney diseases. Therefore, the present study was designed to investigate the possible role of losartan plus oral magnesium sulfate (MgSO4) to reduce CP-induced nephrotoxicity in female rats. The animals were divided into twelve groups: Group 1-6 received saline, MgSO4 (3g/l), MgSO4(10g/l), losartan, MgSO4 (3g/l) plus losartan, MgSO4 (10g/l) plus losartan, respectively. The animals received MgSO4 via drinking water for 9 days. In addition, losartan (10mg/kg/day; i. p.) was accompanied with MgSO4from day 3. Groups 7-12 followed the same regimen of above groups, but CP (2.5mg/kg/day; i. p.) was added to regimen from day 3. At the end of day 9, all animals were sacrificed and the serum levels of blood urea nitrogen (BUN) and creatinine (Cr) were measured. The kidneys were removed rapidly for histopathological study. The Co-administration of losartan and MgSO4 (3g/l) decreased serum Cr and BUN levels in CP treated animals. Also, that was partially attenuated the kidney tissue damage. It was concluded that combination of losartan and MgSO4 (3g/l) may ameliorate kidney function against CP-induced failure.